Phospholipase A2 as targets for anti-cancer drugs

Biochemical Pharmacology

Volumn 74, Issue 7, 2007, Pages 949-959

  Cummings, Brian S ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Arachidonic acid; Carcinogenesis; Cell growth; Lysophosphatidic acid; Phospholipase A2; Tumor formation

Indexed keywords

3 (3 ACETAMIDE 1 BENZYL 2 ETHYLINDOLYL 5 OXY)PROPANE SULFONIC ACID; 4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; ARACHIDONYL TRIFLOUROMETHYL KETONE; BROMOENOL LACTONE; CELECOXIB; CISPLATIN; DYFLOS; GLYCEROPHOSPHOLIPID; LY 311727; LYSOPHOSPHOLIPID; MANOALIDE; METHYLARACHIDONYL FLOUROPHOSPHONATE; MITOGEN ACTIVATED PROTEIN KINASE 6; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLMETHYLSULFONYLFLUORIDE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE C BETA2; PHOSPHOLIPASE C GAMMA2; PROSTAGLANDIN SYNTHASE; REGULATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; PHOSPHOLIPASE A;

ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; COLORECTAL CANCER; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; LIVER CANCER; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SKIN CANCER; THYROID CANCER; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NEOPLASM; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PHOSPHOLIPASES A;

EID: 34548008905     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.021     Document Type: Article

References (108)

1. Cummings B.S., McHowat J., and Schnellmann R.G. Phospholipase A(2)s in cell injury and death. J Pharmacol Exp Ther 294 (2000) 793-799
2. Balsinde J., Winstead M.V., and Dennis E.A. Phospholipase A(2) regulation of arachidonic acid mobilization. FEBS Lett 531 (2002) 2-6
3. Denizot Y., Chianea T., Labrousse F., Truffinet V., Delage M., and Mathonnet M. Platelet-activating factor and human thyroid cancer. Eur J Endocrinol 153 (2005) 31-40
4. Dong Q., Patel M., Scott K.F., Graham G.G., Russell P.J., and Sved P. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 240 (2006) 9-16
5. Laye J.P., and Gill J.H. Phospholipase A2 expression in tumours: a target for therapeutic intervention?. Drug Discov Today 8 (2003) 710-716
6. Yamashita J., Ogawa M., and Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery 117 (1995) 601-608
7. Yamashita S., Yamashita J., and Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69 (1994) 1166-1170
8. Yamashita S., Yamashita J., Sakamoto K., Inada K., Nakashima Y., Murata K., et al. Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71 (1993) 3058-3064
9. Yamashita S., Ogawa M., Sakamoto K., Abe T., Arakawa H., and Yamashita J. Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228 (1994) 91-99
10. Graff J.R., Konicek B.W., Deddens J.A., Chedid M., Hurst B.M., Colligan B., et al. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 7 (2001) 3857-3861
11. Jiang J., Neubauer B.L., Graff J.R., Chedid M., Thomas J.E., Roehm N.W., et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 160 (2002) 667-671
12. Cuendet M., and Pezzuto J.M. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 17 (2000) 109-157
13. Balsinde J., Balboa M.A., Insel P.A., and Dennis E.A. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 39 (1999) 175-189
14. Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 15 (2004) 477-489
15. Balsinde J. Roles of various phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling. Biochem J 364 (2002) 695-702
16. Stewart A., Ghosh M., Spencer D.M., and Leslie C.C. Enzymatic properties of human cytosolic phospholipase A2gamma. J Biol Chem 277 (2002) 29526-29536
17. Ma Z., Wang X., Nowatzke W., Ramanadham S., and Turk J. Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1. J Biol Chem 274 (1999) 9607-9616
18. Mancuso D.J., Jenkins C.M., and Gross R.W. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2). J Biol Chem 275 (2000) 9937-9945
19. Cummings B.S., McHowat J., and Schnellmann R.G. Role of an endoplasmic reticulum Ca(2+)-independent phospholipase A(2) in oxidant-induced renal cell death. Am J Physiol Renal Physiol 283 (2002) F492-F498
20. Jenkins C.M., Mancuso D.J., Yan W., Sims H.F., Gibson B., and Gross R.W. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem 279 (2004) 48968-48975 10.1074/jbc.M407841200
21. Kell P.J., Creer M.H., Crown K.N., Wirsig K., and McHowat J. Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther 307 (2003) 1163-1170
22. Farooqui A.A., Litsky M.L., Farooqui T., and Horrocks L.A. Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders. Brain Res Bull 49 (1999) 139-153
23. Bonventre J.V. Phospholipase A2 and signal transduction. J Am Soc Nephrol 3 (1992) 128-150
24. Bonventre J.V. Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity. J Lipid Mediat Cell Signal 17 (1997) 71-79
25. 2+-independent phospholipase A2 but not cytosolic phospholipase A2, which undergoes proteolytic inactivation. J Biol Chem 273 (1998) 13870-13877
26. Farooqui A.A., and Horrocks L.A. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 12 (2006) 245-260 10.1177/1073858405285923
27. Bao S., Bohrer A., Ramanadham S., Jin W., Zhang S., and Turk J. Effects of Stable Suppression of Group VIA phospholipase A2 expression on phospholipid content and composition, insulin secretion, and proliferation of INS-1 insulinoma cells. J Biol Chem 281 (2006) 187-198 10.1074/jbc.M509105200
28. 2+-independent phospholipase A2 in cell growth and maintenance of phospholipids. J Pharmacol Exp Ther 318 (2006) 1211-1219 10.1124/jpet.106.105650
29. Longo W.E., Grossmann E.M., Erickson B., Panesar N., Mazuski J.E., and Kaminski D.L. The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells. J Surg Res 84 (1999) 51-56
30. Hassan S., and Carraway R.E. Involvement of arachidonic acid metabolism and EGF receptor in neurotensin-induced prostate cancer PC3 cell growth. Regul Pept 133 (2006) 105-114
31. Teslenko V., Rogers M., and Lefkowith J.B. Macrophage arachidonate release via both the cytosolic Ca(2+)-dependent and -independent phospholipases is necessary for cell spreading. Biochim Biophys Acta 1344 (1997) 189-199
32. Xu J., Weng Y.I., Simonyi A., Krugh B.W., Liao Z., Weisman G.A., et al. Role of PKC and MAPK in cytosolic PLA2 phosphorylation and arachadonic acid release in primary murine astrocytes. J Neurochem 83 (2002) 259-270
33. Balsinde J., Balboa M.A., Li W.H., Llopis J., and Dennis E.A. Cellular regulation of cytosolic group IV phospholipase A2 by phosphatidylinositol bisphosphate levels. J Immunol 164 (2000) 5398-5402
34. Ramanadham S., Wolf M.J., Li B., Bohrer A., and Turk J. Glucose-responsitivity and expression of an ATP-stimulatable, Ca(2+)-independent phospholipase A2 enzyme in clonal insulinoma cell lines. Biochim Biophys Acta 1344 (1997) 153-164
35. 2+-independent phospholipase A2 blocks phospholipid fatty acid remodeling in murine P388D1 macrophages. J Biol Chem 272 (1997) 29317-29321
36. Balsinde J., and Dennis E.A. Function and inhibition of intracellular calcium-independent phospholipase A2. J Biol Chem 272 (1997) 16069-16072
37. Balsinde J., and Dennis E.A. Bromoenol lactone inhibits magnesium-dependent phosphatidate phosphohydrolase and blocks triacylglycerol biosynthesis in mouse P388D1 macrophages. J Biol Chem 271 (1996) 31937-31941
38. Sun G.Y., Xu J., Jensen M.D., and Simonyi A. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45 (2004) 205-213
39. Gilroy D.W., Newson J., Sawmynaden P., Willoughby D.A., and Croxtall J.D. A novel role for phospholipase A2 isoforms in the checkpoint control of acute inflammation. Faseb J 18 (2004) 489-498
40. Kudo I., and Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68-69 (2002) 3-58
41. Clark J.D., Lin L.L., Kriz R.W., Ramesha C.S., Sultzman L.A., Lin A.Y., et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 65 (1991) 1043-1051
42. 2+-independent phospholipase A2 augments spontaneous fatty acid release. J Biol Chem 275 (2000) 18248-18258
43. 2+-independent phospholipase A2 in cisplatin-induced renal cell apoptosis. J Pharmacol Exp Ther 308 (2004) 921-928
44. Sapirstein A., Spech R.A., Witzgall R., and Bonventre J.V. Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J Biol Chem 271 (1996) 21505-21513
45. Farooqui A.A., Ong W.Y., and Horrocks L.A. Biochemical aspects of neurodegeneration in human brain: involvement of neural membrane phospholipids and phospholipases A2. Neurochem Res 29 (2004) 1961-1977
46. 2+-induced mitochondrial permeability transition. J Pharmacol Exp Ther 321 (2007) 707-715
47. Balsinde J., Bianco I.D., Ackermann E.J., Conde-Frieboes K., and Dennis E.A. Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 92 (1995) 8527-8531
48. Lands W.E. Lipid metabolism. Annu Rev Biochem 34 (1965) 313-346
49. Meyer M.C., Rastogi P., Beckett C.S., and McHowat J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des 11 (2005) 1301-1312
50. Ackermann E.J., and Dennis E.A. Mammalian calcium-independent phospholipase A2. Biochim Biophys Acta 1259 (1995) 125-136
51. Lio Y.C., Reynolds L.J., Balsinde J., and Dennis E.A. Irreversible inhibition of Ca(2+)-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta 1302 (1996) 55-60
52. Kinsey G.R., Cummings B.S., Beckett C.S., Saavedra G., Zhang W., McHowat J., et al. Identification and distribution of endoplasmic reticulum iPLA2. Biochem Biophys Res Commun 327 (2005) 287-293
53. Song H., Bao S., Ramanadham S., and Turk J. Effects of biological oxidants on the catalytic activity and structure of group VIA phospholipase A2. Biochemistry 45 (2006) 6392-6406
54. 2gamma, as the mediator of arginine vasopressin-induced arachidonic acid release in A-10 smooth muscle cells. Enantioselective mechanism-based discrimination of mammalian iPLA2s. J Biol Chem 277 (2002) 32807-32814
55. Jarvi K., Langlais J., Gagnon C., and Roberts K.D. Platelet-activating factor acetylhydrolase in the male reproductive tract: origin and properties. Int J Androl 16 (1993) 121-127
56. Dentan C., Tselepis A.D., Chapman M.J., and Ninio E. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim Biophys Acta 1299 (1996) 353-357
57. Su X., Mancuso D.J., Bickel P.E., Jenkins C.M., and Gross R.W. Small interfering RNA knockdown of calcium-independent phospholipases A2 beta or gamma inhibits the hormone-induced differentiation of 3T3-L1 preadipocytes. J Biol Chem 279 (2004) 21740-21748
58. Meyer A.M., Dwyer-Nield L.D., Hurteau G.J., Keith R.L., O'Leary E., You M., et al. Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis 25 (2004) 1517-1524
59. Ilsley J.N., Nakanishi M., Flynn C., Belinsky G.S., De Guise S., Adib J.N., et al. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res 65 (2005) 2636-2643
60. Kiyohara H., Egami H., Kako H., Shibata Y., Murata K., Ohshima S., et al. Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas. Int J Pancreatol 13 (1993) 49-57
61. Oka Y., Ogawa M., Matsuda Y., Murata A., Nishijima J., Miyauchi K., et al. Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors. Enzyme 43 (1990) 80-88
62. Kallajoki M., Alanen K.A., Nevalainen M., and Nevalainen T.J. Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 35 (1998) 263-272
63. Ying Z., Tojo H., Komatsubara T., Nakagawa M., Inada M., Kawata S., et al. Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma. Biochim Biophys Acta 1226 (1994) 201-205
64. Dimberg J., Samuelsson A., Hugander A., and Soderkvist P. Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer. Anticancer Res 18 (1998) 3283-3287
65. 2g2a confers resistance to intestinal tumorigenesis. Nat Genet 17 (1997) 88-91
66. MacPhee M., Chepenik K.P., Liddell R.A., Nelson K.K., Siracusa L.D., and Buchberg A.M. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81 (1995) 957-966
67. Kennedy B.P., Soravia C., Moffat J., Xia L., Hiruki T., Collins S., et al. Overexpression of the nonpancreatic secretory group II PLA2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res 58 (1998) 500-503
68. Wendum D., Svrcek M., Rigau V., Boelle P.Y., Sebbagh N., Parc R., et al. COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas. Mod Pathol 16 (2003) 130-136
69. Kawamoto S., Shoji M., Setoguchi Y., Kato M., Hashizume S., Ichikawa A., et al. Molecular cloning of the 31 kDa cytosolic phospholipase A2, as an antigen recognized by the lung cancer-specific human monoclonal antibody, AE6F4. Cytotechnology 17 (1995) 103-108
70. Pirianov G., Danielsson C., Carlberg C., James S.Y., and Colston K.W. Potentiation by vitamin D analogs of TNFalpha and ceramide-induced apoptosis in MCF-7 cells is associated with activation of cytosolic phospholipase A2. Cell Death Differ 6 (1999) 890-901
71. 2+-independent phospholipase A2. Biochim Biophys Acta 1391 (1998) 384-400
72. 2+-independent phospholipase A2 on chemotherapeutic-induced death and phospholipid profiles in renal cells. Biochem Pharmacol 70 (2005) 1697-1706
73. Peterson B., Knotts T., and Cummings BS. Involvement of Ca(2+)-independent phospholipase A(2) isoforms in oxidant-induced neural cell death. Neurotoxicology (2006)
74. Denizot Y., Truffinet V., Bouvier S., Gainant A., Cubertafond P., and Mathonnet M. Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer. Mediators Inflamm 13 (2004) 53-54
75. Denizot Y., De Armas R., Caire F., Pommepuy I., Truffinet V., and Labrousse F. Platelet-activating factor and human meningiomas. Neuropathol Appl Neurobiol 32 (2006) 674-678
76. Nigam S., Muller S., and Benedetto C. Elevated plasma levels of platelet-activating factor (PAF) in breast cancer patients with hypercalcemia. J Lipid Mediat 1 (1989) 323-328
77. Biancone L., Cantaluppi V., Del Sorbo L., Russo S., Tjoelker L.W., and Camussi G. Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res 9 (2003) 4214-4220
78. Seeds M.C., and Bass D.A. Regulation and metabolism of arachidonic acid. Clin Rev Allergy Immunol 17 (1999) 5-26
79. Umezu-Goto M., Tanyi J., Lahad J., Liu S., Yu S., Lapushin R., et al. Lysophosphatidic acid production and action: validated targets in cancer?. J Cell Biochem 92 (2004) 1115-1140
80. Bonventre J.V. Roles of phospholipases A2 in brain cell and tissue injury associated with ischemia and excitotoxicity. J Lipid Mediat Cell Signal 14 (1996) 15-23
81. McHowat J., and Creer M.H. Catalytic features, regulation and function of myocardial phospholipase A2. Curr Med Chem Cardiovasc Hematol Agents 2 (2004) 209-218
82. Imig J.D. Epoxygenase metabolites. Epithelial and vascular actions. Mol Biotechnol 16 (2000) 233-251
83. Barry O.P., Pratico D., Lawson J.A., and FitzGerald G.A. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 99 (1997) 2118-2127
84. Haimovich B., Ji P., Ginalis E., Kramer R., and Greco R. Phospholipase A2 enzymes regulate alpha IIb beta3-mediated, but not Fc gammaRII receptor-mediated, pp125FAK phosphorylation in platelets. Thromb Haemost 81 (1999) 618-624
85. Creer M.H., and McHowat J. Selective hydrolysis of plasmalogens in endothelial cells following thrombin stimulation. Am J Physiol 275 (1998) C1498-C1507
86. Wang D., and Dubois R.N. Prostaglandins and cancer. Gut 55 (2006) 115-122
87. Spector A.A., and Norris AW. Action of epoxyeicosatrienoic acids (EETs) on cellular function. Am J Physiol Cell Physiol 292 (2007) C996-C1012
88. Yuan C.J., Mandal A.K., Zhang Z., and Mukherjee A.B. Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. Cancer Res 60 (2000) 1084-1091
89. Liou J.Y., Aleksic N., Chen S.F., Han T.J., Shyue S.K., and Wu K.K. Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res 306 (2005) 75-84
90. Suh Y.J., Chada S., McKenzie T., Liu Y., Swisher S.G., Lucci A., et al. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery 138 (2005) 422-430
91. Murakami M., Masuda S., Shimbara S., Ishikawa Y., Ishii T., and Kudo I. Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2). J Biol Chem 280 (2005) 24987-24998
92. Xu L., Han C., and Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem 281 (2006) 33982-33996
93. Wendum D., Comperat E., Boelle P.Y., Parc R., Masliah J., Trugnan G., et al. Cytoplasmic phospholipase A2 alpha overexpression in stromal cells is correlated with angiogenesis in human colorectal cancer. Mod Pathol 18 (2005) 212-220
94. Jiang W.G., Douglas-Jones A., and Mansel R.E. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 275-281
95. Kim J.H., Hubbard N.E., Ziboh V., and Erickson K.L. Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein. Biochim Biophys Acta 1736 (2005) 244-250
96. Carraway R.E., Hassan S., and Cochrane D.E. Regulation of neurotensin receptor function by the arachidonic acid-lipoxygenase pathway in prostate cancer PC3 cells. Prostaglandins Leukot Essent Fatty Acids 74 (2006) 93-107
97. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 315 (2004) 624-635
98. Liu B., Maher R.J., Hannun Y.A., Porter A.T., and Honn K.V. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. J Natl Cancer Inst 86 (1994) 1145-1151
99. Nony P.A., Kennett S.B., Glasgow W.C., Olden K., and Roberts J.D. 15S-Lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK. J Biol Chem 280 (2005) 31413-31419
100. Kuwata H., Nonaka T., Murakami M., and Kudo I. Search of factors that intermediate cytokine-induced group IIA phospholipase A2 expression through the cytosolic phospholipase A2- and 12/15-lipoxygenase-dependent pathway. J Biol Chem 280 (2005) 25830-25839
101. Karlgren M., and Ingelman-Sundberg M. Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin Ther Targets 11 (2007) 61-67
102. Jiang J.G., Chen C.L., Card J.W., Yang S., Chen J.X., Fu X.N., et al. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65 (2005) 4707-4715
103. Okamoto T., Momose S., and Hino O. Suppression of cytochrome P450 1A1 and 4A1 gene expression in renal carcinomas of TSC2 gene mutant (Eker) rats. Int J Oncol 18 (2001) 147-149
104. Tollet P., Hamberg M., Gustafsson J.A., and Mode A. Growth hormone signaling leading to CYP2C12 gene expression in rat hepatocytes involves phospholipase A2. J Biol Chem 270 (1995) 12569-12577
105. Seree E., Villard P.H., Pascussi J.M., Pineau T., Maurel P., Nguyen Q.B., et al. Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology 127 (2004) 1436-1445
106. Kim H.S., Ishizuka M., Kazusaka A., and Fujita S. Alterations of activities of cytosolic phospholipase A2 and arachidonic acid-metabolizing enzymes in di-(2-ethylhexyl)phthalate-induced testicular atrophy. J Vet Med Sci 66 (2004) 1119-1124
107. Aoki J., Taira A., Takanezawa Y., Kishi Y., Hama K., Kishimoto T., et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem 277 (2002) 48737-48744
108. Eder A.M., Sasagawa T., Mao M., Aoki J., and Mills G.B. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 6 (2000) 2482-2491